News

Myasthenia Gravis Eye Research

We are thrilled to share a landmark win for the Australian myasthenia gravis (MG) community: the Pharmaceutical Benefits Advisory Committee (PBAC) has officially recommended all four new MG treatments for listing on the Pharmaceutical Benefits Scheme (PBS).

All across Queensland, landmarks will light up in teal throughout June to shine a light on Myasthenia Gravis.

Here’s where you can catch the glow:

📸 Spot a teal-lit landmark? Tag us in your photos on social media to spread awareness!
 

Please note: Dates may change at the discretion of each venue.

It’s almost here! In just 11 days, the MGAQ is proud to host a special Celebration Day for Chloe’s inspiring “Oh MG” Art Exhibition, and you’re warmly invited.

Bring your family, friends, and medical team to experience a powerful showcase that celebrates the strength, resilience, and creativity of the Myasthenia Gravis (MG) community.

Read the full patient

Late last year, many people in our community participated in a survey conducted by Alexion Pharmaceuticals about the impact of generalised Myasthenia Gravis (gMG) on daily life and experiences with healthcare professionals. 
 
The survey found gMG has a significant impact on people’s social, personal and professional life with one in two retiring early. Restricted social life, loss of independence and the ability to plan activities were the most reported impacts.

Living with MG means navigating a complex treatment journey. While we’ve come a long way with effective therapies like steroids, immunosuppressants, IVIG, and surgery, not all patients respond the same way.